Managing B-Cell Malignancies with BTK Inhibitors: Patient-Centered Drug Selection

Managing B-Cell Malignancies with BTK Inhibitors: Patient-Centered Drug Selection

November 22, 2021, 1 to 2pm, Dartmouth Hitchcock Medical Center, Lebanon, NH

Audience:       

Accredited for Pharmacists

Other interested health care professionals welcome

Credits:          

1 Contact Hour knowledge based

0.1CEU will be awarded under the provider

0837-9999-21-236-L01-P                                  

Presenter:

Julia Rumley, PharmD, PGY1 Pharmacy Resident, Dartmouth Hitchcock

Registration:

Free to all attendees

Learning Objectives:

After attending this program, participants will be able to:

1. Describe the mechanisms of action of BTK inhibitors leading to adverse effects and treatment efficacy against B-cell malignancies
2. Identify indications and risks associated with use of ibrutinib, acalabrutinib, and zanubrutinib
3. Select a BTK inhibitor based on malignancy type and patient risk factors

Requirements for Receiving CE Credit:

• Successful completion of post-presentation questions
• Participation at live program
• Complete program evaluation form